Adcom gives Karyopharm a second chance with selinexor
Incredibly, a US FDA panel has left the door open for approval of Karyopharm’s selinexor in multiple myeloma, despite concerns about safety.
Big pharma execs decry rebates, but how big might list price cuts be?
Executives were pressed to lower prices in a post-rebate world, but a broad commitment to offset rebates did not materialise.
Xeljanz warning Jaks up safety concerns
An increased risk of blood clots and death with Pfizer’s drug could also bode ill for newer Jak inhibitors.
Regeneron and Sanofi play follow the leader on Praluent pricing
Amgen has set the stage for low-hassle access to new cholesterol-lowering agents, leaving little choice for competitors.
The list of shame no biopharma wants to join
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
No price relief in 2019, Pfizer confirms
The biggest of big pharma companies has added to the downbeat tone for the year. Drug makers need to keep thinking on pricing.
Brilinta could finally get a chance to shine
A value-based deal would boost prices should Astrazeneca's struggling heart-disease pill Brilinta outperform outcomes benchmarks.
Gene therapy: how much will it cost patients?
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
Topping 2018 drug approvals will be a tall order
Was 2018 as good as it gets for drug approvals, or is the pipeline so stellar that even a US government shutdown cannot stop biopharma?
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.